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Although the mortality due to stomach cancer has decreased
significantly over the last 5 decades in the USA and Western
Europe, stomach cancer remains the leading cause of cancer
mortality worldwide. Complete resection of the tumour is the
treatment of choice, and an effective adjuvant treatment regimen
has not been established (Hermans et al, 1993). The tumour stage
is the most important factor in predicting patient survival after the
surgery. We are in need of other biological markers that can predict
patient survival and identify subsets of patients who might benefit
from different therapeutic approaches.
DNA flow cytometry is a quantitative measure of DNA content
(ploidy) and proliferative activity (S-phase fraction, SPF) of a
tumour, and is hypothetically likely to give information regarding
the subsequent clinical course of a patient with that particular
tumour (Merkel et al, 1987). The measurement of tumour ploidy
and tumour cell proliferation by DNA flow cytometry has been
performed on a variety of human tumours in the past and shown to
correlate with the prognosis of patients in several types of
tumours, including colon and breast cancers (Look et al, 1988;
Sigurdsson et al, 1990; Haffty et al, 1992; Bauer et al, 1993).
Tumour SPF showed clear correlations with risk of recurrence and
mortality for patients with both node-negative and node-positive
breast cancer. Tumour ploidy of breast cancer also showed correla-
tion with the prognosis of patients, although the magnitude of the
difference was small (Hedley et al, 1993). Recent consensus
review, however, did not recommend DNA flow cytometry for the
routine management of colorectal and breast cancer, due to the
lack of sufficient data showing the independent prognostic value
of DNA flow cytometry (Bast et al, 1996). In stomach cancer,
there have been numerous studies correlating DNA flow cytom-
etry with patient prognosis. Several studies showed that patients
with stomach cancer with an aneuploid tumour cell population or
with a higher proliferative activity had worse prognoses (Tosi et al,
1988; Bronzo et al, 1989; Korenaga et al, 1989; Nanus et al, 1989;
Wyatt et al, 1989; Yonemura et al, 1990; Baretton et al, 1991;
Kimura and Yonemura, 1991; Johnson Jr et al, 1993; Kakeji et al,
1993; Rugge et al, 1994; Yonemura et al, 1994; D’Agnano et al,
1995; Flyger et al, 1995; Ikeguchi et al, 1995; Sakusabe et al,
1996; Victorzon et al, 1996). Other studies failed to show such
correlation (Sasaki et al, 1989; Filipe et al, 1991; Sarbia et al,
1996). Most of these studies were performed in a retrospective
manner using archived, paraffin-embedded tissues.
To ascertain the role of DNA flow cytometry as a prognostic
indicator for patients with stomach cancer, we initiated a prospec-
tive study evaluating the roles of tumour ploidy and SPF for
stomach cancer prognoses. The results are presented after a
median follow-up of over 5 years.
MATERIALS AND METHODS
Between November 1990 and December 1992, primary stomach
cancer tissues were obtained from fresh resection specimens of
217 patients. During sampling of the tumours from the resected
stomach, a pathologist examined the specimens grossly. The
samples were taken from the middle portions of the bisected
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Correspondence to: KH Leetumours, avoiding necrotic areas. Stromal tissues were excluded as
much as possible. At the discretion of the pathologists, specimens
with very small lesions were not included in the study, because
sampling of such lesions may have hindered accurate pathologic
examinations. In 215 cases, normal-appearing, tumour-free
mucosa was also obtained from each specimen to be used as a
control. Various clinical characteristics of the patients such as age,
sex, duration of symptom, history of upper gastrointestinal
bleeding, history of gastric outlet obstruction, history of weight
loss, Karnofsky performance status, serum haemoglobin level,
serum albumin level and serum creatinine level, were collected.
History of bleeding and obstruction was determined to be present
clinically by the presence of symptoms of haematemesis, melena,
or persistent vomiting. Weight loss was determined to be present
if the patient lost over 10% of his or her body weight during a
6 month period before the diagnosis of stomach cancer. Various
pathologic characteristics of the tumours, such as size, location
in the stomach, stage, and histologic differentiation, were also
collected. The tumours were staged according to the American
Joint Committee on Cancer classification (Beahrs et al, 1988).
Lauren’s histologic type (Lauren, 1965) was determined retrospec-
tively by a pathologist in a blind manner.
DNA ploidy and SPF were determined by DNA flow cytometry
as previously described (Lee et al, 1993). Samples were frozen
rapidly in polypropylene screw-cap tubes, and stored in a freezer
at – 80°C. On the day of analysis, the samples were thawed rapidly
in a water bath at 37°C (Vindeløv et al, 1983a). Cell suspensions
were prepared from the tumour and normal mucosa by mincing or
scraping with a blade in RPMI 1640 (Gibco, Grand Island, NY,
USA) in petri dishes, then sieving through a 30 mm nylon mesh to
remove tissue fragments and cell clusters. The dissociated cells
were centrifuged at 300 g for 10 min and adjusted to 1–2 ´ 106
cells ml–1 with RPMI 1640. Nuclear staining was done according
to the methods described by Vindeløv et al (1983b). In brief, the
stock solution was prepared by dissolving trisodium citrate
dihydrate (Merck, Darmstadt, Germany), 2000 mg (3.4 mmol l–1),
Nonidet P 40 (Shell, Carrington, UK), 2000 ml (0.1% vv–1),
sperminetetrahydrochloride (Sigma, St. Louis, MO, USA), 1044
mg (1.5 mmol l–1), and tris(hydroxymethyl)-aminomethane
(Sigma), 121 mg (0.5 mmol l–1) in distilled water to make a total
volume of 2000 ml. The pH was adjusted to 7.6. Solution A was
made by adding trypsin (Sigma), 15 mg in 500 ml of stock solu-
tion, and the pH was adjusted to 7.6. Solution B was made by
adding trypsin inhibitor (Sigma), 250 mg, and ribonuclease A
(Sigma), 50 mg, to 500 ml of stock solution, and the pH was
adjusted to 7.6. For solution C, propidium iodide (Calbiochem,
San Diego, CA, USA), 208 mg and sperminetetrahydrochloride,
580 mg were added to 500 ml of stock solution, and the pH was
adjusted to 7.6. Solution C was protected against light with tin foil
during preparation, storage, and the staining procedure. The solu-
tions were stored in 5 ml aliquots in plastic tubes at –80°C. Before
use, the solutions were thawed in a water bath at 37°C. Solutions
A and B were then kept at room temperature until use. Solution C
was kept in an ice bath. Solution A, 900 ml, was added to 100 ml of
the cell suspension in citrate buffer and the tube was inverted to
mix the contents gently. After 10 min at room temperature, during
which the tube was inverted five to six times, solution B, 750 ml,
was added. The solutions were again mixed by inversion of the
tube, and after 10 min at room temperature, 750 ml of ice-cold
solution C was added. The solutions were mixed, and the sample
was filtered through a 30 mm nylon mesh into tubes wrapped in tin
foil for protection of the propidium iodide against light. The
samples were kept in an ice bath until analysis. The samples were
run in the flow cytometer between 15 min and 3 h after the
completion of staining.
The flow cytometer, FACScan (Becton Dickinson, Sunnyvale,
CA, USA), was calibrated before daily use using ethanol-fixed
chicken erythrocyte nuclei stained with propidium iodide. The
following parameters were recorded: forward-angle light scatter,
side scatter, orange-red fluorescence (FL2)-width, and FL2-area.
Gating protocol was not employed. To construct each histogram,
at least 20 000 events were examined after the exclusion of back-
ground, aggregates, and debris (BAD), which did not exceed 20%
of the total acquired events. The G0/G1 peak of diploid cell
population was set in a channel number over 50. The results were
stored on disk for further analysis. The presence and the type of
aneuploidy were determined according to the criteria and defini-
tion of Dressler et al (1989). DNA aneuploidy was determined to
be present when two clearly-defined G0/G1 peaks were seen on a
DNA histogram. DNA Index (DI) was defined as a ratio between
the modal channel number for the DNA aneuploid and diploid
peaks. DNA aneuploidy was further classified into five categories:
simple hyperdiploidy (DI > 1.00; ≤ 1.90), near-tetraploidy (DI >
1.90;  ≤ 2.20), hypodiploidy (DI < 1.00), hypertetraploidy
(DI > 2.20), and multiploidy (more than 1 aneuploid peak). The
SPF was obtained according to the Cellfit Software User’s guide
(Becton Dickinson Immunocytometry System, San Jose, CA,
USA). For diploid samples, the SOBR model was used. For
samples with aneuploid population, the POLY model was used.
The SPF could not be obtained if the cell cycle distribution of the
sample did not fit the model used. A full peak coefficient of varia-
tion for the G0/G1 peak was calculated for each sample using
same software supplied by Becton Dickinson.
Frequencies of aneuploidy of tumours with various clinical
characteristics and pathologic status were compared using
chi-square (c2) analysis. The SPF of tumours were compared using
the Student t-test or analysis of variance test after log conversion.
The primary end points in this study were disease-specific survival
(DSS) and overall survival (OS). DSS was defined as the interval
between the surgery and the death due to stomach cancer. Patients
who died from causes other than stomach cancer were censored at
the time of the death for the calculation of DSS. OS was defined as
the interval between the surgery and the death due to any cause.
Survival curves of the patients were obtained by the Kaplan-Meier
method and compared using generalized Wilcoxon test. Follow-up
duration of patients who were alive at the time of the analysis were
considered in the calculation of the median follow-up time. For the
multivariate analysis, the Cox proportional hazards regression
model was used to evaluate the predictive power of various combi-
nations of prognostic factors.
RESULTS
Patients
There were 148 male and 69 female patients, a total of 217
patients. The median age of the patients was 55 years (range
24–78). Of the 217 patients, grossly complete resection of tumour
was possible in 197 patients. In the remaining 20 patients, gastric
resection was palliative. One hundred and fifty patients received
adjuvant chemotherapy (5-fluorouracil plus cisplatin in 84
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oral tegafur/uracil in 41; and etoposide plus 5-fluorouracil plus
leucovorin in one).
Coefficient of variation of the G0/G1 peak
The overall mean of the coefficient of variation of the G0/G1 peak
was 3.45 (range 0.01–7.20) for the samples from the normal
mucosa, and 3.41 (range 0.56–6.46) for the tumours.
Ploidy
All the 215 samples from the normal mucosa gave diploid
histograms. In contrast, 114 of 217 samples (53%) from the
stomach cancers gave aneuploid tracings. Among 114 aneuploid
samples, there were 91 simple hyperdiploid (mean DI 1.45, range
1.06–1.90), four hypodiploid (DI 0.69, 0.88, 0.88, and 0.94 respec-
tively), eight near-tetraploid (mean DI 2.04, range 1.94–2.18), four
hypertetraploid (DI 2.41, 2.48, 2.53, and 3.10 respectively), and
seven multiploid.
Moderately well differentiated tumours had a significantly
higher frequency of aneuploidy compared to well differentiated or
undifferentiated tumours (P = 0.001, Table 1). In terms of Lauren’s
histologic type, intestinal type stomach cancer had a significantly
higher frequency of aneuploidy compared to diffuse type
(P = 0.001, Table 1). No significant difference was observed in the
frequency of aneuploidy in terms of various clinical characteristics
of the patients such as age, sex, Karnofsky performance status,
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Table 1 Patient characteristics and ploidy
Characteristics Frequency of aneuploidy (%) P value
Total 114/217 (53)
Age (yr) 0.195
≤ 40 14/34 (41)
41–50 20/46 (43)
51–60 36/57 (63)
61–70 30/55 (55)
> 70 14/25 (56)
Sex 0.125
Male 83/148 (56)
Female 31/69 (45)
Karnofsky performance status 0.299
100 2/7 (29)
90 46/79 (58)
80 46/85 (53)
70 or less 18/43 (42)
Tumour size (mm) 0.178
< 40 16/38 (42)
40–54 36/57 (63)
55–79 32/59 (54)
³ 80 30/63 (48)
Tumour location 0.385
Upper third 8/19 (42)
Middle third 23/41 (56)
Lower third 78/143 (55)
Diffuse 4/12 (33)
TNM stage 0.202
Ia 4/14 (29)
Ib 13/24 (54)
II 18/39 (46)
IIIa 21/40 (53)
IIIb 36/68 (53)
IV 23/32 (69)
Histologic grade 0.001
Well differentiated 6/13 (46)
Moderately well differentiated 38/51 (75)
Poorly differentiated 64/127 (50)
Undifferentiated 4/21 (19)
Histologic type (Lauren) 0.001
Intestinal 52/74 (70)
Diffuse 41/102 (40)
Mixed 21/40 (53)
Table 2 S-Phase fraction and clinicopathologic findings
Characteristics n Mean %S* Range P value
Total 157 14.1 0–51.9
Age (yr) 0.245
≤ 40 28 13.2 0–49.2
41–50 34 12.9 2.1–51.9
51–60 38 15.1 0–45.0
61–70 35 13.4 0.9–34.0
> 70 22 15.8 6.0–29.9
Sex 0.579
Male 101 13.8 0–45.0
Female 56 14.7 1.2–51.9
Karnofsky performance status 0.023
100 6 6.8 0.9–16.8
90 53 13.4 0–45.0
80 65 13.9 0–51.9
70 or less 33 16.9 4.2–49.2
Tumour size (mm) 0.586
< 40 31 16.4 2.6–51.9
40–54 39 14.2 0.9–34.0
55–79 44 14.4 0–49.2
³ 80 32 12.8 2.3–30.8
Tumour location 0.848
Upper third 14 11.8 3.3–32.4
Middle third 31 14.7 2.1–39.3
Lower third 103 14.4 0–51.9
Diffuse 9 12.4 2.3–22.8
TNM stage 0.744
Ia 13 12.9 0–32.4
Ib 17 15.6 0–51.9
II 27 12.5 0–29.4
IIIa 31 12.0 0.9–32.4
IIIb 48 14.9 1.2–38.1
IV 21 17.1 4.2–49.2
Histologic grade 0.406
Well differentiated 11 11.9 2.1–25.5
Moderately well differentiated 32 12.7 0–32.4
Poorly differentiated 92 15.3 0–51.9
Undifferentiated 18 13.9 0–39.3
Histologic type (Lauren) 0.451
Intestinal 48 13.7 0–45.0
Diffuse 80 14.1 1.2–51.9
Mixed 28 14.6 0–49.2
Ploidy 0.087
Diploid 96 12.8 1.6–49.2
Aneuploid 62 16.2 0–51.9
*S-phase fractionduration of symptom, history of bleeding, history of gastric outlet
obstruction, history of weight loss, serum haemoglobin level,
serum albumin level, and serum creatinine level. Pathologic vari-
ables such as tumour size, tumour location in the stomach, and
TNM stage also failed to show significant difference in the
frequency of aneuploidy (part of the data shown in Table 1).
S-Phase fraction
The SPF was obtained in 213 of 215 samples from normal mucosa,
96 of 103 diploid tumours (93%) and 61 of 114 aneuploid tumours
(54%) (157 of 217 tumours, 72%, in total). The overall mean of
the SPF for the tumours was 14.1% (range 0–51.9), which is
higher than that of normal mucosa (4.15%, range 0.5–31.2). The
mean SPF of aneuploid tumours (16.2%, range 0–51.9) was higher
than that of diploid tumours (12.8%, range 1.6–49.2), but the
difference was not statistically significant (P = 0.087, Table 2).
The patients with poorer performance status had tumours with
significantly higher SPF (P = 0.023, Table 2). There was no
significant difference in SPF in terms of other clinical as well as
pathologic variables (part of the data shown in Table 2).
Survival analysis
The median follow-up time of patients who were alive at the time
of the analysis was 66.1 months (range 29.5–78.1). Of 217
patients, 110 patients (50.7%) were alive. Eight patients died
without clinical evidence of recurrent or persistent stomach cancer
and were censored for the analysis of DSS. Three patients died of
postoperative complications. Each of the remaining five patients
died of the following causes: sepsis after adjuvant chemotherapy,
pneumonia, hepatitis B virus associated liver failure, suicidal
intoxication, and trauma.
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Table 3 Univariate analysis: characteristics influencing disease-specific and overall survival (I)
Disease-specific survival Overall survival
Characteristics Censored (%) P value* Alive (%) P value*
Age (yr) 0.369 0.204
≤ 40 15/34 (44) 15/34 (44)
41–50 25/46 (54) 25/46 (54)
51–60 35/57 (61) 33/57 (58)
61–70 29/55 (53) 26/55 (47)
> 70 14/25 (56) 11/25 (44)
Sex 0.020 0.022
Male 87/148 (59) 81/148 (55)
Female 31/69 (45) 29/69 (42)
Karnofsky performance status 0.015 0.006
100 7/7 (100) 7/7 (100)
90 42/79 (53) 41/79 (52)
80 48/85 (56) 45/85 (53)
70 or less 21/46 (46) 17/46 (37)
Duration of symptom (mo) 0.419 0.473
< 2 38/67 (57) 37/67 (55)
2–2.9 18/41 (44) 17/41 (41)
3–5.9 28/55 (51) 26/55 (47)
³ 6 33/51 (65) 29/51 (57)
History of bleeding 0.498 0.210
Yes 16/34 (47) 12/34 (35)
No 102/183 (56) 98/183 (54)
History of pyloric obstruction < 0.001 < 0.001
Yes 10/33 (30) 8/33 (24)
No 108/184 (59) 102/184 (55)
History of weight loss 0.006 0.004
Yes 38/86 (44) 33/86 (38)
No 80/131 (61) 77/131 (59)
Serum haemoglobin level (g/dl) 0.101 0.033
< 11 30/55 (55) 27/55 (49)
11–12.5 25/56 (45) 21/56 (38)
12.6–13.9 28/53 (53) 27/53 (51)
³ 14 35/53 (66) 35/53 (66)
Serum albumin level (g/dl) 0.179 0.092
< 3.4 21/40 (53) 18/40 (45)
3.4–3.7 17/38 (45) 14/38 (37)
3.8–4.0 33/60 (55) 32/60 (53)
³ 4.1 45/74 (61) 44/74 (59)
Serum creatinine level (mg/dl) 0.319 0.433
< 0.8 19/43 (44) 18/43 (42)
0.8–0.89 17/28 (61) 16/28 (57)
0.9–0.99 28/57 (49) 27/57 (47)
³ 1 53/84 (63) 48/84 (57)
*Generalized Wilcoxon testUnivariate analysis of prognostic factors
The results of univariate analysis of various clinicopathologic
characteristics of the patients are presented in Tables 3 and 4. For
the purpose of survival analysis, tumour SPFs were divided into
three groups: low (less than 8%), intermediate (8–17%), and high
(over 17%). The factors affecting DSS were sex (P = 0.020),
Karnofsky performance status (P = 0.015), history of pyloric
obstruction (P < 0.001), history of weight loss (P = 0.006), tumour
size (P = 0.041), tumour location in the stomach (P < 0.001),
T stage (P < 0.001), N stage (P < 0.001), TNM stage (P < 0.001),
Lauren’s histologic type (P = 0.037), and tumour SPF (P = 0.007).
There was no significant difference between survivals of those
patients with diploid tumours and aneuploid tumours (55 vs 54%
of the patients censored, P = 0.410, Table 4 and Figure 1A). Those
patients with tumours with an SPF over 17% had a significantly
poorer DSS than those with tumours with SPFs of lower than 8%
or 8–17% (45 vs 59 and 63%, P = 0.007, Table 4 and Figure 1B).
The factors affecting OS were similar to those affecting DSS,
except that serum haemoglobin level was an additional prognostic
indicator for OS (P = 0.033, Table 3 and Figure 2A and 2B).
Multivariate analysis
For the regression analyses, the following variables were consid-
ered in the variable selection process; age, sex, Karnofsky perfor-
mance status, history of pyloric obstruction, history of weight loss,
serum haemoglobin level, tumour size, tumour location, TNM
stage, Lauren’s histologic type, and tumour SPF. TNM stage
remained most important indicator for DSS and OS. Tumour SPF
was a significant independent variable along with tumour location
(Table 5). The relative risk of dying from the disease for those
patients with tumours with an SPF higher than 17% was 2.300
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Table 4 Univariate analysis: characteristics influencing disease-specific and overall survival (II)
Disease-specific survival Overall survival
Characteristics Censored (%) P value* Alive (%) P value*
Tumour size (mm) 0.041 0.022
< 40 28/38 (74) 28/38 (74)
40–54 31/57 (54) 28/57 (49)
55–79 32/59 (54) 30/59 (51)
³ 80 27/63 (43) 24/63 (38)
Tumour location < 0.001 < 0.001
Upper third 10/19 (53) 9/19 (47)
Middle third 25/41 (61) 23/41 (56)
Lower third 81/143 (57) 77/143 (54)
Diffuse 1/12 (8) 0/12 (0)
T stage < 0.001 < 0.001
T1 20/21 (95) 19/21 (90)
T2 30/33 (91) 29/33 (88)
T3 57/130 (44) 53/130 (41)
T4 11/33 (33) 9/33 (27)
N stage < 0.001 < 0.001
N0 53/65 (82) 51/65 (78)
N1 38/65 (58) 36/65 (55)
N2 27/87 (31) 23/87 (26)
TNM stage < 0.001 < 0.001
Ia 14/14 (100) 14/14 (100)
Ib 23/24 (96) 22/24 (92)
II 27/39 (69) 25/39 (64)
IIIa 25/40 (63) 23/40 (58)
IIIb 21/68 (31) 19/68 (28)
IV 8/32 (25) 7/32 (22)
Histologic grade 0.607 0.597
Well differentiated 9/13 (69) 9/13 (69)
Moderately well differentiated 30/51 (59) 28/51 (55)
Poorly differentiated 66/127 (52) 60/127 (47)
Undifferentiated 10/21 (48) 10/21 (48)
Histologic type (Lauren) 0.037 0.024
Intestinal 49/74 (66) 47/74 (64)
Diffuse 48/102 (47) 43/102 (42)
Mixed 21/40 (53) 20/40 (50)
Ploidy 0.410 0.306
Diploid 57/103 (55) 54/103 (52)
Aneuploid 61/114 (54) 56/114 (49)
S-phase fraction 0.007 0.004
< 8% 29/49 (59) 28/49 (57)
8–17% 37/59 (63) 35/59 (59)
> 17% 22/49 (45) 20/49 (40)
*Generalized Wilcoxon test(95% CI, 1.252–4.223) when compared to those patients with
tumours with SPF lower than 8%. The relative risks of those
patients with tumours with SPFs lower than 8% and 8–17% were
similar (Table 5). Further analyses were done to investigate the
effect of tumour SPF on DSS in each subset of patients in TNM
stage. Tumour SPF had most significant influence in T3, N2, and
overall stage III subsets of patients (Table 6).
DISCUSSION
Our current study is the first in the literature investigating the
prognostic value of tumour ploidy and SPF in patients with
stomach cancer in a prospective manner in a large number of
patients. The median follow-up duration is over 5 years. The coef-
ficient of variation of the G0/G1 peak in our study was sufficiently
low and comparable to other published data using fresh samples
(Vindeløv et al, 1983a). It is well within 8%, which is usually
recommended as an upper limit for useful SPF determinations
(Shankey et al, 1993). Our findings confirm previous reports
showing that the proliferative activity of tumour cells in stomach
cancer is a prognostic factor (Yonemura et al, 1990; Yonemura et
al, 1994; Victorzon et al, 1996). Furthermore, upon multivariate
analysis, SPF was an independent prognostic indicator along with
the TNM stage (Table 5). The relative risk of those patients with
tumours with an SPF over 17% dying from stomach cancer was
approximately twice that of patients with tumours with SPFs of
lower than 8% or 8–17% (Table 5). Further analyses of patients in
the subsets of the TNM stage confirmed that tumour SPF had most
significant predictive power in T3, N2 and overall stage III subsets
of patients, where new prognostic indicators are needed most
(Table 6). The SPF could be obtained in 158 of 218 tumours (72%)
in our series. When we compared two subgroups of patients with
or without an obtainable tumour SPF, there was no significant
difference in terms of various clinical and pathologic variables, as
well as the DSS and OS of the patients (data not shown).
Tumour SPF showed significant correlation with the Karnofsky
performance status of the patients (P = 0.023, Table 2). There was
no correlation between tumour SPF and pathologic variables such
as tumour size, TNM stage, and histologic grade. These findings
suggest that tumour SPF is not dependent upon tumour progres-
sion or degree of histologic differentiation.
Our recent literature search retrieved 20 studies correlating
tumour ploidy to patient survival in stomach cancer. Of those 20
studies, 17 studies found the presence of correlation between tumour
ploidy and the survival of the patients, while the rest did not.
Yonemura et al (1990) analysed the largest number of samples (493
samples) from paraffin-embedded tissues and found that tumour
1732 KH Lee et al
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Figure 1 Kaplan-Meier survival curves depicting disease-specific survival in
patients with stomach cancer. (A) Tumour ploidy versus disease-specific
survival. (B) Tumour S-phase fraction versus disease-specific survival
Figure 2 Kaplan-Meier survival curves depicting overall survival in patients
with stomach cancer. (A) Tumour ploidy versus overall survival. (B) Tumour
S-phase fraction versus overall survivalploidy correlated with variables that are associated with tumour
extent, such as serosal invasion, nodal spread, liver metastasis, and
peritoneal metastasis, as well as patient survival. Multivariate
analyses showed that tumour ploidy was an independent prognostic
factor. Nanus et al (1989) analysed 50 tumour samples obtained
from surgery and found that tumour ploidy correlated with disease-
free survival of the patients, vertical tumour location in the stomach,
and sex of the patients. There were no correlations with either depth
of invasion of the tumour or nodal involvement.
In contrast to previous studies, we did not find correlation
between tumour ploidy and patient survival. It is now well known
that stomach cancers are heterogeneous in terms of etiology as
well as epidemiology. The patient population in our study is
typical of those found in high-incidence areas, i.e. the tumours are
predominantly located in the distal part of the stomach. The reduc-
tion in the incidence of stomach cancer in the USA and Western
Europe in the last five decades is attributable to a decline in distal
lesions (Fenoglio-Preiser et al, 1996). Studies from the low-inci-
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Table 5 Results of multivariate analyses
Relative risk (95% CI) for death
Characteristics Disease-specific survival Overall survival
Sex
Male
Female 1.177 (0.705–1.9632) 1.118 (0.684–1.828)
History of weight loss
Yes
No 0.979 (0.587–1.631) 0.892 (0.549–1.450)
Tumour location
Upper third
Middle third 0.316 (0.112–0.892)* 0.373 (0.135–1.031)
Lower third 0.437 (0.172–1.114) 0.532 (0.213–1.331)
Diffuse 0.941 (0.286–3.097) 1.230 (0.393–3.848)
TNM stage
I
II 9.297 (1.092–79.122)* 12.396 (1.517–101.266)*
IIIa 14.564 (1.835–115.600)* 17.778 (2.275–138.949)*
IIIb 46.606 (6.100–356.078)* 46.312 (6.113–350.855)*
IV 68.236 (8.4797–549.162)* 64.284 (8.076–511.689)*
Histologic type (Lauren)
Intestinal
Diffuse 1.376 (0.719–2.636) 1.313 (0.712–2.423)
Mixed 1.118 (0.498–2.511) 0.927 (0.426–2.021)
S-phase fraction
< 8%
8–17% 1.087 (0.569–2.076) 1.158 (0.621–2.161)
17% 2.300 (1.252–4.223)* 2.350 (1.306–4.230)*
*P < 0.05
Table 6 Disease-specific survival according to TNM stage and tumour S-phase fraction
Tumour S-phase fraction
TNM Stage < 8% 8–17% > 17% P value*
T stage
T1 7/7 (100)** 4/4 (100) 6/6 (100) –
T2 6/6 (100) 9/11 (82) 5/5 (100) 0.351
T3 14/31 (45) 21/36 (58) 8/31 (26) 0.002
T4 2/5 (40) 3/8 (38) 3/7 (43) 0.309
N stage
N0 15/18 (83) 18/21 (86) 11/12 (92) 0.894
N1 9/11 (82) 12/19 (63) 8/14 (57) 0.347
N2 5/20 (25) 7/19 (37) 3/23 (13) 0.015
TNM stage
I 11/11 (100) 9/10 (90) 9/9 (100) 0.368
II 6/9 (67) 10/12 (83) 5/6 (83) 0.901
III 8/22 (36) 18/32 (56) 6/25 (24) 0.008
IV 4/7 (57) 0/5 (0) 2/9 (22) 0.274
III + IV 12/29 (41) 18/37 (49) 8/34 (24) 0.002
*Generalized Wilcoxon test. **The numbers show the fractions of patients who are censored (%).dence area (Nanus et al, 1989; Johnson Jr et al, 1993) showed that
42–46% of the patients in the series had stomach cancers located
in the cardia, in contrast to our study where the patients with
tumours located in the upper third of the stomach comprised only
9%. The difference in the pathogenesis of stomach cancers found
between high- and low-incidence areas may reflect the different
results between studies. In the studies of Nanus et al (1989) and
Johnson Jr et al (1993), the frequency of aneuploidy of the
tumours located in the cardia-gastro-oesophageal junction was
found to be higher than that of tumours located in the body-antrum
area of the stomach (95 vs 48%, and 39 vs 20%, respectively). We
did not find such a correlation between the frequency of aneu-
ploidy and the location of the tumour in the stomach (Table 1).
When subsets of patients with stomach cancers located in the
upper third or upper and middle thirds of the stomach were
analysed, we did not find a significant difference in the survival of
the patients according to tumour ploidy (data not shown).
The discrepancies between studies from high-incidence areas
and our current study cannot be explained by the difference in the
pathogenesis of stomach cancers. All of the studies from high-
incidence areas which showed positive correlation between
tumour ploidy and the survival of the patients were done in a retro-
spective manner using archived, paraffin-embedded tissues. In
order to have a high level of evidence for the prognostic value of a
biologic tumour marker and to evaluate the relative significance of
such a role in relation to other known prognostic factors, it is of
utmost importance to perform the study in a prospectively
controlled manner so that there would be less chance of introduc-
tion of compounding factors. Our data is in agreement with those
of Sasaki et al (1989) who performed DNA flow cytometry on 70
fresh surgical specimens, which showed a correlation between
tumour ploidy and differentiation, but no correlation with patient
prognosis.
In our study, tumour ploidy did not show correlation with patho-
logic variables that are associated with tumour progression, i.e.
tumour size or TNM stage. However, tumour ploidy showed corre-
lation with tumour grade and Lauren’s histologic type. A higher
frequency of aneuploidy in intestinal type stomach cancer in
contrast to diffuse type (70% vs 40%, P = 0.001, Table 1) in our
study is in agreement with a recent theory of carcinogenesis of
intestinal type stomach cancer which proposed a multistep process
involving metaplasia and dysplasia of gastric epithelium, along
with associated genetic changes (Correa, 1992). Moderately well
differentiated tumours in our study showed a significantly higher
frequency of aneuploidy compared to well differentiated or undif-
ferentiated tumours. The data, however, should be interpreted
cautiously, because the frequency of aneuploidy did not change
unidirectionally with the change in degree of tumour differentia-
tion. In the study of Sasaki et al (1989), well differentiated
tumours had fewer cases of aneuploidy when compared to poorly
differentiated tumours, although the number of cases is small.
These data need to be confirmed by further studies.
It should be noted that the patient population in our study is not
representative of the population of patients with stomach cancer as
a whole. Patients with very small lesions in the stomach were not
included, because sampling of such lesions may hinder accurate
pathologic examination. Patients with M1 lesions were also under-
represented in our study, because samples were obtained from
surgically resected stomach, thus excluding patients with clinically
inoperable metastatic diseases. Most patients with advanced stage
disease in our series received combination chemotherapy after the
surgery. The impact that chemotherapy may have on the analysis
of the outcome cannot be determined.
It has been reported that 33–40% of primary stomach cancers
are heterogeneous in terms of tumour ploidy (Sasaki et al, 1988;
De Aretxabala et al, 1989). Systematic investigation of the
variation of SPF within primary stomach cancer has not been
reported. Further studies are needed to determine the degree of
heterogeneity of primary stomach cancer in terms of tumour SPF.
In conclusion, our study showed that tumour ploidy obtained by
DNA flow cytometry did not provide prognostic information in
patients with stomach cancer in a high-incidence area. On the
other hand, tumour SPF was an independent prognostic factor
for DSS and OS of patients with stomach cancer. Further pros-
pectively controlled studies are warranted to confirm the prog-
nostic value of tumour SPF in stomach cancer, especially in
high-incidence areas.
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